<DOC>
	<DOCNO>NCT01054781</DOCNO>
	<brief_summary>The purpose study evaluate complete response ( CR ) rate Intensified 1st cycle Rituximab plus 3rd cycle R-CHOP DLBCL</brief_summary>
	<brief_title>Intensified 1st Cycle Rituximab Plus 8th Cycles R-CHOP Chemotherapy Patients With Advanced Bulky CD20+ Diffuse Large B-cell Lymphoma ( DLBCL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Inclusion criterion 1 . Histologically confirm CD20 positive Diffuse Large Bcell Lymphoma ( DLBCL ) 2 . Advanced stage : stage III , IV and/or bulky disease ( large diameter ≥ 10.0 cm ) regardless stage 3 . Previously untreated . 4 . Performance status : ECOG 02 . 5 . Age ≥ 18 6 . At least one bidimensionally measurable lesion ( ) ≥ 2 cm conventional CT ≥ 1 cm spiral CT skin lesion ( photograph take ) ≥ 2 cm measurable lesion physical examination ≥ 2 cm 7 . Cardiac ejection fraction ≥ 50 % measure MUGA 2D ECHO without clinically significant abnormality 8 . Adequate renal function : serum creatinine level &lt; 2 mg/dL ( 177 μmol/L ) 9 . Adequate liver function : Transaminase ( AST/ALT ) &lt; 3 X upper normal value ( &lt; 5 x ULN presence DLBCL involvement liver ) Bilirubin &lt; 2 X upper normal value ( &lt; 5 x ULN presence DLBCL involvement liver ) 10 . Adequate hematological function : hemoglobin ≥ 9 g/dL absolute neutrophil count ( ANC ) ≥ 1,500/μL platelet count ≥ 75,000/μL , unless abnormality due bone marrow involvement lymphoma 11 . Life expectancy ≥ 6 month 12 . A negative serum urine pregnancy test prior treatment must available pre menopausal woman woman &lt; 1 year onset menopause . 13 . Informed consent Exclusion criterion 1 . Other subtypes NHL DLBCL 2 . Patients transform follicular lymphoma indolent lymphoma 3 . Primary Central Nervous System ( CNS ) DLBCL ; 4 . CNS involvement lymphoma evidence spinal cord compression . Brain CT/MRI mandatory ( within 4 week ) case clinical suspicion CNS involvement lymphoma . Patients prophylactic intrathecal chemotherapy CNS disease eligible . 5 . Patients known history HIV seropositivity HCV ( + ) . Patients HBV ( + ) eligible . However , primary prophylaxis use antiviral agent ( i.e . lamivudine ) recommend HBV carrier prevent HBV reactivation whole treatment period . 6 . Any malignancy within past 5 year except curatively treat nonmelanoma skin cancer situ carcinoma cervix uteri 7 . Pregnant lactate woman , woman childbearing potential employ adequate contraception 8 . Other serious illness medical condition Unstable cardiac disease despite treatment , myocardial infarction within 6 month prior study entry History significant neurological psychiatric disorder include dementia seizure Active uncontrolled infection ( viral , bacterial fungal infection ) Other serious medical illness 9 . Known hypersensitivity study drug ingredient ( i.e. , hypersensitivity Polysorbate 20 , CHO cell product , recombinant human antibody ) 10 . Concomitant administration experimental drug investigation , concomitant chemotherapy , hormonal therapy , immunotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Diffuse Large B-Cell Lymphoma ( DLBCL )</keyword>
	<keyword>rituximab</keyword>
	<keyword>CHOP</keyword>
</DOC>